Skip to main content

Table 1 Descriptive characteristics of the entire cohort and stratified by hormonal status

From: The impact of chemotherapy dose intensity and supportive care on the risk of febrile neutropenia in patients with early stage breast cancer: a prospective cohort study

Characteristics All patients ER+ or PR+ ER− and PR−
n (%) n (%) n (%)
Totala 1,202 767 387
Age
 <50 years 452 (37.6) 281 (36.6) 150 (38.8)
 50–64 years 546 (45.4) 357 (46.5) 170 (43.9)
 ≥65 years 204 (17.0) 129 (16.8) 67 (17.3)
Menopausal statusa
 Pre-menopausal 486 (40.7) 316 (41.5) 146 (37.8)
 Post-menopausal 709 (59.3) 446 (58.5) 240 (62.2)
Race
 White 961 (80.0) 629 (82.0) 297 (76.7)
 Black 153 (12.7) 88 (11.5) 58 (15.0)
 Other 88 (7.3) 50 (6.5) 32 (8.3)
Baseline body surface area
 ≤2 m2 930 (77.4) 595 (77.6) 298 (77.0)
 >2 m2 272 (22.6) 172 (22.4) 89 (23.0)
Body mass indexa
 <30 kg/m2 769 (64.1) 499 (65.3) 238 (61.5)
 30 to <35 kg/m2 226 (18.8) 136 (17.8) 81 (20.9)
 ≥35 kg/m2 204 (17.0) 129 (16.9) 68 (17.6)
ECOG performance status
 0 937 (78.0) 608 (79.3) 295 (76.2)
 1 241 (20.0) 145 (18.9) 84 (21.7)
 2–4 24 (2.0) 14 (1.8) 8 (2.1)
Stagea
 I 288 (24.1) 188 (24.6) 96 (25.0)
 II 678 (56.7) 437 (57.1) 218 (56.8)
 III 230 (19.2) 140 (18.3) 70 (18.2)
Medical history
 Prior chemotherapy 98 (8.2) 49 (6.4) 46 (11.9)
 Recent surgery 565 (47.0) 354 (46.2) 188 (48.6)
 Diabetes 96 (8.0) 55 (7.2) 36 (9.3)
 CHF or MI 24 (2.0) 16 (2.1) 5 (1.3)
 Lung disease 30 (2.5) 18 (2.3) 11 (2.8)
 History of anemia 85 (7.1) 57 (7.4) 23 (5.9)
Number of comorbidities
 0 1,027 (85.4) 659 (85.9) 329 (85.0)
 1 153 (12.7) 97 (12.6) 49 (12.7)
 ≥2 22 (1.8) 11 (1.4) 9 (2.3)
Chemotherapy treatment
 Standard AC or EC 527 (43.8) 334 (43.5) 170 (43.9)
 Dose dense AC or EC 137 (11.4) 82 (10.7) 51 (13.2)
 CMF 123 (10.2) 90 (11.7) 31 (8.0)
 CAF or CEF 155 (12.9) 105 (13.7) 47 (12.1)
 TAC or TEC 83 (6.9) 54 (7.0) 27 (7.0)
 Paclitaxel/docetaxel 68 (5.7) 41 (5.3) 25 (6.5)
 AT or ET 42 (3.5) 22 (2.9) 16 (4.1)
 Other 67 (5.6) 39 (5.1) 20 (5.2)
  1. ECOG Eastern Cooperative Group performance status, ER estrogen receptor, PR progesterone receptor, MI myocardial infarction, CHF congestive heart failure, A doxorubicin, C cyclophosphamide, E epirubicin, F 5-flourouracil, M methotrexate, T docetaxel.
  2. aFor some variables sample size is smaller due to missing data, including 48 patients with unknown hormonal status.